[Analysis of the clinical efficacy of vaccination against pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with type 2 diabetes mellitus].
G L IgnatovaE V BlinovaV N AntonovPublished in: Terapevticheskii arkhiv (2022)
Vaccination of pneumococcal infection in patients with COPD and type 2 diabetes mellitus can reduce the number of exacerbations, incidence of pneumonia and the number of hospitalizations, improve the prognosis and survival of patients using PCV-13 by maintaining efficacy for 5 years of follow-up.
Keyphrases
- chronic obstructive pulmonary disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- cystic fibrosis
- prognostic factors
- peritoneal dialysis
- risk factors
- lung function
- cardiovascular disease
- type diabetes
- patient reported outcomes
- metabolic syndrome
- intensive care unit
- glycemic control
- skeletal muscle
- weight loss
- free survival
- air pollution
- extracorporeal membrane oxygenation